A new framework for patient engagement in cancer clinical trials cooperative group studies

Patricia A. Deverka, Rick Bangs, Karma Kreizenbeck, Deborah M. Delaney, Dawn L. Hershman, Charles Blanke, Scott D. Ramsey

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

For the past two decades, the National Cancer Institute (NCI) has supported the involvement of patient advocates in both internal advisory activities and funded research projects to provide a patient perspective. Implementation of the inclusion of patient advocates has varied considerably, with inconsistent involvement of patient advocates in key phases of research such as concept development. Despite this, there is agreement that patient advocates have improved the patient focus of many cancer research studies. This commentary describes our experience designing and pilot testing a new framework for patient engagement at SWOG, one of the largest cancer clinical trial network groups in the United States and one of the four adult groups in the NCI's National Clinical Trials Network (NCTN). Our goal is to provide a roadmap for other clinical trial groups that are interested in bringing the patient voice more directly into clinical trial conception and development. We developed a structured process to engage patient advocates more effectively in the development of cancer clinical trials and piloted the process in four SWOG research committees, including implementation of a new Patient Advocate Executive Review Form that systematically captures patient advocates' input at the concept stage. Based on the positive feedback to our approach, we are now developing training and evaluation metrics to support meaningful and consistent patient engagement across the SWOG clinical trial life cycle. Ultimately, the benefits of more patient-centered cancer trials will be measured in the usefulness, relevance, and speed of study results to patients, caregivers, and clinicians.

Original languageEnglish (US)
Pages (from-to)553-559
Number of pages7
JournalJournal of the National Cancer Institute
Volume110
Issue number6
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Patient Participation
Clinical Trials
Neoplasms
Research
National Cancer Institute (U.S.)
Life Cycle Stages
Caregivers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Deverka, P. A., Bangs, R., Kreizenbeck, K., Delaney, D. M., Hershman, D. L., Blanke, C., & Ramsey, S. D. (2018). A new framework for patient engagement in cancer clinical trials cooperative group studies. Journal of the National Cancer Institute, 110(6), 553-559. https://doi.org/10.1093/jnci/djy064

A new framework for patient engagement in cancer clinical trials cooperative group studies. / Deverka, Patricia A.; Bangs, Rick; Kreizenbeck, Karma; Delaney, Deborah M.; Hershman, Dawn L.; Blanke, Charles; Ramsey, Scott D.

In: Journal of the National Cancer Institute, Vol. 110, No. 6, 01.01.2018, p. 553-559.

Research output: Contribution to journalReview article

Deverka, PA, Bangs, R, Kreizenbeck, K, Delaney, DM, Hershman, DL, Blanke, C & Ramsey, SD 2018, 'A new framework for patient engagement in cancer clinical trials cooperative group studies', Journal of the National Cancer Institute, vol. 110, no. 6, pp. 553-559. https://doi.org/10.1093/jnci/djy064
Deverka, Patricia A. ; Bangs, Rick ; Kreizenbeck, Karma ; Delaney, Deborah M. ; Hershman, Dawn L. ; Blanke, Charles ; Ramsey, Scott D. / A new framework for patient engagement in cancer clinical trials cooperative group studies. In: Journal of the National Cancer Institute. 2018 ; Vol. 110, No. 6. pp. 553-559.
@article{2ae20018f2f140b08b59d4b18170c1ab,
title = "A new framework for patient engagement in cancer clinical trials cooperative group studies",
abstract = "For the past two decades, the National Cancer Institute (NCI) has supported the involvement of patient advocates in both internal advisory activities and funded research projects to provide a patient perspective. Implementation of the inclusion of patient advocates has varied considerably, with inconsistent involvement of patient advocates in key phases of research such as concept development. Despite this, there is agreement that patient advocates have improved the patient focus of many cancer research studies. This commentary describes our experience designing and pilot testing a new framework for patient engagement at SWOG, one of the largest cancer clinical trial network groups in the United States and one of the four adult groups in the NCI's National Clinical Trials Network (NCTN). Our goal is to provide a roadmap for other clinical trial groups that are interested in bringing the patient voice more directly into clinical trial conception and development. We developed a structured process to engage patient advocates more effectively in the development of cancer clinical trials and piloted the process in four SWOG research committees, including implementation of a new Patient Advocate Executive Review Form that systematically captures patient advocates' input at the concept stage. Based on the positive feedback to our approach, we are now developing training and evaluation metrics to support meaningful and consistent patient engagement across the SWOG clinical trial life cycle. Ultimately, the benefits of more patient-centered cancer trials will be measured in the usefulness, relevance, and speed of study results to patients, caregivers, and clinicians.",
author = "Deverka, {Patricia A.} and Rick Bangs and Karma Kreizenbeck and Delaney, {Deborah M.} and Hershman, {Dawn L.} and Charles Blanke and Ramsey, {Scott D.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/jnci/djy064",
language = "English (US)",
volume = "110",
pages = "553--559",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - A new framework for patient engagement in cancer clinical trials cooperative group studies

AU - Deverka, Patricia A.

AU - Bangs, Rick

AU - Kreizenbeck, Karma

AU - Delaney, Deborah M.

AU - Hershman, Dawn L.

AU - Blanke, Charles

AU - Ramsey, Scott D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - For the past two decades, the National Cancer Institute (NCI) has supported the involvement of patient advocates in both internal advisory activities and funded research projects to provide a patient perspective. Implementation of the inclusion of patient advocates has varied considerably, with inconsistent involvement of patient advocates in key phases of research such as concept development. Despite this, there is agreement that patient advocates have improved the patient focus of many cancer research studies. This commentary describes our experience designing and pilot testing a new framework for patient engagement at SWOG, one of the largest cancer clinical trial network groups in the United States and one of the four adult groups in the NCI's National Clinical Trials Network (NCTN). Our goal is to provide a roadmap for other clinical trial groups that are interested in bringing the patient voice more directly into clinical trial conception and development. We developed a structured process to engage patient advocates more effectively in the development of cancer clinical trials and piloted the process in four SWOG research committees, including implementation of a new Patient Advocate Executive Review Form that systematically captures patient advocates' input at the concept stage. Based on the positive feedback to our approach, we are now developing training and evaluation metrics to support meaningful and consistent patient engagement across the SWOG clinical trial life cycle. Ultimately, the benefits of more patient-centered cancer trials will be measured in the usefulness, relevance, and speed of study results to patients, caregivers, and clinicians.

AB - For the past two decades, the National Cancer Institute (NCI) has supported the involvement of patient advocates in both internal advisory activities and funded research projects to provide a patient perspective. Implementation of the inclusion of patient advocates has varied considerably, with inconsistent involvement of patient advocates in key phases of research such as concept development. Despite this, there is agreement that patient advocates have improved the patient focus of many cancer research studies. This commentary describes our experience designing and pilot testing a new framework for patient engagement at SWOG, one of the largest cancer clinical trial network groups in the United States and one of the four adult groups in the NCI's National Clinical Trials Network (NCTN). Our goal is to provide a roadmap for other clinical trial groups that are interested in bringing the patient voice more directly into clinical trial conception and development. We developed a structured process to engage patient advocates more effectively in the development of cancer clinical trials and piloted the process in four SWOG research committees, including implementation of a new Patient Advocate Executive Review Form that systematically captures patient advocates' input at the concept stage. Based on the positive feedback to our approach, we are now developing training and evaluation metrics to support meaningful and consistent patient engagement across the SWOG clinical trial life cycle. Ultimately, the benefits of more patient-centered cancer trials will be measured in the usefulness, relevance, and speed of study results to patients, caregivers, and clinicians.

UR - http://www.scopus.com/inward/record.url?scp=85054511718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054511718&partnerID=8YFLogxK

U2 - 10.1093/jnci/djy064

DO - 10.1093/jnci/djy064

M3 - Review article

C2 - 29684151

AN - SCOPUS:85054511718

VL - 110

SP - 553

EP - 559

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -